{"filing":{"accession_number":"0001171843-26-004096","cik":"0000882796","ticker":"BCRX","company_name":"BIOCRYST PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"f8k_061226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/f8k_061226.htm"},"events":[{"id":10777,"run_id":9455,"accession_number":"0001171843-26-004096","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BioCryst Pharmaceuticals held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four matters: election of three directors (Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse), ratification of Ernst \u0026 Young LLP as independent auditors, an advisory vote on executive compensation, and approval of an amended and restated Stock Incentive Plan increasing available shares by 7,000,000 shares. All proposals passed with detailed vote tallies disclosed.","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7174,"accession_number":"0001171843-26-004096","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amended and restated Stock Incentive Plan increasing available shares by 7,000,000 shares. This is a compensatory arrangement affecting equity grants to directors and officers, falling squarely within Item 5.02(e) scope. The material increase in share authorization and shareholder approval make this material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:02.731680+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7175,"accession_number":"0001171843-26-004096","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 11, 2026, covering four matters: election of three directors (Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse), ratification of Ernst \u0026 Young LLP as independent auditors, advisory vote on executive compensation, and approval of the Incentive Plan Proposal. The detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the hallmark of Item 5.07 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:02.731680+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7174,"accession_number":"0001171843-26-004096","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amended and restated Stock Incentive Plan increasing available shares by 7,000,000 shares. This is a compensatory arrangement affecting equity grants to directors and officers, falling squarely within Item 5.02(e) scope. The material increase in share authorization and shareholder approval make this material to investors assessing dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:02.731680+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-12"},{"id":7175,"accession_number":"0001171843-26-004096","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 11, 2026, covering four matters: election of three directors (Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse), ratification of Ernst \u0026 Young LLP as independent auditors, advisory vote on executive compensation, and approval of the Incentive Plan Proposal. The detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the hallmark of Item 5.07 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:02.731680+00:00","company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","filing_date":"2026-06-12"}]}